{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:34:10Z","timestamp":1769600050069,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T00:00:00Z","timestamp":1428710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s40272-015-0129-1","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T10:25:45Z","timestamp":1428661545000},"page":"315-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review"],"prefix":"10.1007","volume":"17","author":[{"given":"Lesleigh S.","family":"Abbott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furqan","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Shewaramani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Punnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Lee","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,11]]},"reference":[{"issue":"12","key":"129_CR1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.leu.2401980","volume":"14","author":"LB Silverman","year":"2000","unstructured":"Silverman LB, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981\u20131995). Leukemia. 2000;14(12):2247\u201356.","journal-title":"Leukemia"},{"issue":"5","key":"129_CR2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211\u20138.","journal-title":"Blood"},{"issue":"5","key":"129_CR3","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/14712591003769808","volume":"10","author":"M Rytting","year":"2010","unstructured":"Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther. 2010;10(5):833\u20139.","journal-title":"Expert Opin Biol Ther"},{"key":"129_CR4","first-page":"532","volume":"21","author":"EE Haley","year":"1961","unstructured":"Haley EE, Fischer GA, Welch AD. The requirement for l-asparagine of mouse leukemia cells L5178Y in culture. Cancer Res. 1961;21:532\u20136.","journal-title":"Cancer Res"},{"issue":"3","key":"129_CR5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/pbc.23380","volume":"59","author":"M Pidaparti","year":"2012","unstructured":"Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatric Blood Cancer. 2012;59(3):436\u20139.","journal-title":"Pediatric Blood Cancer"},{"issue":"8","key":"129_CR6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MPH.0b013e31822d4d4e","volume":"33","author":"J Kurtzberg","year":"2011","unstructured":"Kurtzberg J, et al. Polyethylene glycol-conjugated l-asparaginase versus native l-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children\u2019s Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"129_CR7","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study.[Erratum appears in Blood 2002 Sep 1;100(5):1531]. Blood. 2002;99(6):1986\u201394.","journal-title":"Blood"},{"issue":"1","key":"129_CR8","first-page":"9","volume":"1","author":"M Nesbit","year":"1979","unstructured":"Nesbit M, et al. Evaluation of intramuscular versus intravenous administration of l-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1(1):9\u201313.","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"7","key":"129_CR9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","volume":"115","author":"LB Silverman","year":"2010","unstructured":"Silverman LB, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351\u20133.","journal-title":"Blood"},{"issue":"7","key":"129_CR10","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","volume":"109","author":"D Douer","year":"2007","unstructured":"Douer D, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55\u00a0years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744\u201350.","journal-title":"Blood"},{"key":"129_CR11","unstructured":"Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Cancer National Institute, May 28, 2009 (V4.03: June 14, 2010)."},{"issue":"4","key":"129_CR12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/08880018.2013.876134","volume":"31","author":"WC Petersen Jr","year":"2014","unstructured":"Petersen WC Jr, et al. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31(4):311\u20137.","journal-title":"Pediatr Hematol Oncol"},{"issue":"7","key":"129_CR13","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1097\/MPH.0b013e31828e5471","volume":"35","author":"KJ August","year":"2013","unstructured":"August KJ, et al. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration. J Pediatr Hematol Oncol. 2013;35(7):e283\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"S2","key":"129_CR14","first-page":"171","volume":"61","author":"T MacDonald","year":"2014","unstructured":"MacDonald T, et al. Significantly higher incidence of allergic reactions for intravenous peg-asparaginase as compared to intramuscular peg-asparaginase in children with high risk acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61(S2):171.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"129_CR15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1365-2125.2010.03774.x","volume":"71","author":"BY Thong","year":"2011","unstructured":"Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011;71(5):684\u2013700.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"129_CR16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","volume":"124","author":"CA Fernandez","year":"2014","unstructured":"Fernandez CA, et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood. 2014;124(8):1266\u201376.","journal-title":"Blood"},{"issue":"1","key":"129_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","volume":"110","author":"JK Armstrong","year":"2011","unstructured":"Armstrong JK, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2011;110(1):103\u201311.","journal-title":"Cancer"},{"issue":"1","key":"129_CR18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.reval.2011.08.003","volume":"52","author":"L Guilleminault","year":"2012","unstructured":"Guilleminault L, et al. Positive skin test to pegylated drug in a patient with anaphylaxis to polyethylene glycol. Rev Fr Allergol. 2012;52(1):45\u20137.","journal-title":"Rev Fr Allergol"},{"key":"129_CR19","doi-asserted-by":"crossref","unstructured":"Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant. 2003;18 Suppl 8:837\u201341.","DOI":"10.1093\/ndt\/gfg1091"},{"issue":"2","key":"129_CR20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/10428194.2010.537796","volume":"52","author":"H Berg van den","year":"2011","unstructured":"van den Berg H. Asparaginase revisited. Leuk Lymphoma. 2011;52(2):168\u201378.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"129_CR21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","volume":"55","author":"ML Graham","year":"2003","unstructured":"Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003;55(10):1293\u2013302.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"129_CR22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","volume":"26","author":"EH Panosyan","year":"2004","unstructured":"Panosyan EH, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children\u2019s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217\u201326.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"129_CR23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1023\/A:1008368916800","volume":"11","author":"C Rizzari","year":"2000","unstructured":"Rizzari C, et al. l-asparagine depletion and l-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli l-asparaginase as first exposure. Ann Oncol. 2000;11(2):189\u201393.","journal-title":"Ann Oncol"},{"issue":"8","key":"129_CR24","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3109\/10428194.2010.494316","volume":"51","author":"M Strullu","year":"2010","unstructured":"Strullu M, et al. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2010;51(8):1464\u201372.","journal-title":"Leuk Lymphoma"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-015-0129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-015-0129-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-015-0129-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T18:22:31Z","timestamp":1598898151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-015-0129-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,11]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1007\/s40272-015-0129-1","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,11]]}}}